

## Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

**Product: MEDTECH FAM FUND (the "Sub-Fund"), a sub-fund of FAM Series UCITS ICAV (the "ICAV").**

**PRIIP Manufacturer:** Fineco Asset Management DAC (the "Manager") which is part of FinecoBank Group.

**ISIN:** IE0008L3YSW8 LH Acc - EUR Hedged Accumulating

**Website:** www.finecoassetmanagement.com

**Telephone Number:** Call +353 1 574 7459 or +353 1 574 7455 for more information.

The Central Bank of Ireland is responsible for supervising the Manager in relation to this Key Information Document (KID). This Sub-Fund is authorized in Ireland. The Manager is authorized in Ireland and regulated by the Central Bank of Ireland.

**Investment Manager:** CPR Asset Management

**KID production date:** 18/12/2023

## What is this product?

**Type:** UCITS

**Term:** There is no fixed term for this Sub-Fund.

**Objectives:** The investment objective of the Sub-Fund is to provide capital appreciation over the long term. The Sub-Fund seeks to achieve its objective by investing in a diversified portfolio of global equity securities of companies involved in the medical technology ecosystem that can demonstrate their ability to comply with international sectoral standards for ESG. In actively managing The Sub-Fund, the Investment Manager will invest at least 75% of its net assets in equity and equity-linked securities of any country, without constraints of capitalization. Among this proportion of 75% of its assets, the Sub-Fund may invest in China A shares via Stock Connect within a maximum of 25% of its assets. The Sub-Fund may use derivatives for hedging, investment purposes and/or efficient portfolio management. The recommended holding period has been selected as the link between the risk and the potential returns of the Sub-Fund and can be fully appreciated only over the recommended holding period. The Sub-Fund is actively managed. There can be no guarantee that the investment objective will actually be attained. Investors can redeem their shares on the relevant Dealing Day as set out in the prospectus. Investors can ask for full or partial redemption of the shares held. **SFDR Classification :** The Sub-Fund is classified as an Article 8 financial product under SFDR. For more detailed information on the ESG components of the Sub-Fund as well as the integration of sustainability risks into the investment decision process, please refer to the supplement and to the ICAV prospectus. **Benchmark Information:** The Investment Manager has selected the MSCI World Health Care Equipment and Supplies 10/40 Index NR ("Index") that will be used as a comparison for the investment performance only. The Investment Manager does not intend to replicate the composition of such Index and may at all times exercise total freedom by investing in securities which are not included in the referenced Index or which are present in different proportions.

**Intended retail investor:**

- With a basic knowledge of investing in funds and no or limited experience of investing in the Sub-Fund or similar funds
- Who understand the risk of losing some or all of the capital invested
- This Sub-Fund may not be appropriate for investors who plan to withdraw their money before the recommended holding period

## What are the risks and what could I get in return?



- The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because the Sub-Fund is not able to pay you.
- We have classified this product as 5 out of 7, which is a medium-high risk class.
- This rates the potential losses from future performance at a medium-high level, and poor market conditions are very unlikely to impact the capacity of the Sub-Fund to pay you.
- This product does not include any protection from future market performance so you could lose some or all of your investment.
- If the ICAV is not able to pay you what is owed, you could lose your entire investment.

## Performance Scenarios

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted. The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product / a suitable benchmark over the last 10 years. Markets could develop very differently in the future.

The performances indicated in each of the proposed scenarios consider the application of any entry fees, and for the maximum amount envisaged by the prospectus, as indicated in the section below referring to costs and entitled: "Composition of Costs".

Recommended holding period: 5 years

Example Investment: € 10,000

Scenarios		If you cash in after 1 year	If you cash in after 5 years
<b>Minimum</b>	<b>There is no minimum guaranteed return</b>		
<b>Stress</b>	<b>What you might get back after costs</b>	<b>€ 1,730</b>	<b>€ 1,890</b>
	Average return each year	-82.66%	-28.36%
<b>Unfavourable</b>	<b>What you might get back after costs</b>	<b>€ 6,470</b>	<b>€ 6,880</b>
	Average return each year	-35.30%	-7.21%
<b>Moderate</b>	<b>What you might get back after costs</b>	<b>€ 10,800</b>	<b>€ 18,240</b>
	Average return each year	7.99%	12.77%
<b>Favourable</b>	<b>What you might get back after costs</b>	<b>€ 14,540</b>	<b>€ 22,990</b>
	Average return each year	45.43%	18.11%

- The figures shown include all the costs of the product itself and includes the costs of your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.
- The stress scenario shows what you might get back in extreme market circumstances.
- The unfavorable scenario at 5 years occurred for an investment in the product/applicable benchmark between October 2021 and November 2023. The moderate scenario at 5 years occurred for an investment in the product/applicable benchmark between October 2015 and October 2020. The favorable scenario at 5 years occurred for an investment in the product/applicable benchmark between April 2014 and April 2019.

## What happens if Fineco Asset Management DAC is unable to pay out?

If the Manager were to become insolvent, the assets of the Sub-Fund should not be affected because they are held by the Depositary, which is legally required to keep the assets separate from its own assets and those of the Manager. However, if the Depositary were to become insolvent, there may be a financial loss for the Sub-Fund, but this should be minimized because the assets are held separate to the Depositary's own assets. If the Sub-Fund is closed or dissolved, the assets will be sold and the investors will receive a share of the proceeds, which may be more or less than their initial investment. The ICAV is not a guaranteed UCITS and as a result there is no guarantee scheme in place which provides a guaranteed rate of return. The Sub-Fund does not provide compensation or operate a guarantee against any loss in the value of an investment, the funds or any income generated.

## What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

### Costs over Time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product. The amounts shown here are illustrations based on an example investment amount and different investment periods. We have assumed:

- In the first year, you would get back the amount that you invested (0% annual return). For the other holding period we have assumed the product performs as shown in the moderate scenario.
- 10000 EUR is invested.

	If you cash in after 1 year	If you cash in after 5 years
<b>Total costs</b>	<b>€ 704</b>	<b>€ 1,864</b>
<b>Annual cost impact (*)</b>	<b>7.4%</b>	<b>3.3% each year</b>

(\*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 16.10% before costs and 12.80% after costs.

## Composition of Costs

One-off costs upon entry or exit		If you exit after 1 year
<b>Entry costs</b>	5.00% of the amount you pay in when entering this investment.	€ 500
<b>Exit costs</b>	We do not charge an exit fee for this product.	€ 0
Ongoing costs taken each year		
<b>Management fees and other administrative or operating costs</b>	1.95% of the value of your investment per year. Due to the lack of this Fund's operating history, this is an estimate only.	€ 185
<b>Transaction costs</b>	0.20% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	€ 19
Incidental costs taken under specific conditions		
<b>Performance fees</b>	There is no performance fee for this product.	€ 0

## How long should I hold it and can I take money out early?

Recommended holding period: 5 years

The recommended holding period of the Sub-Fund is expected to be 5 years. The recommended holding period of 5 years is based on the liquidity profile of the Sub-Fund as well as the risk profile of the underlying assets. Investors can redeem their units on the relevant Dealing Day as set out in the prospectus by placing an order with the Distributor. No fees or penalties are applied by the Manager.

## How can I complain?

In relation to complaints about the person advising on or selling the Sub-Fund, investors can request information, complain and/or make comments free of charge by contacting FinecoBank S.p.A. In relation to complaints about the Sub-Fund or the conduct of the Manager, complainants can request information, complain and/or make comments free of charge by contacting the Manager. Any complaints, claims or comments may be provided in writing, in Italian or English, together with supporting documents to the following (as applicable): FinecoBank S.p.A: Piazza Durante 11, 20131 Milan, or by email to: [helpdesk@finecobank.com](mailto:helpdesk@finecobank.com) or [finecobankspa.pec@actaliscertymail.it](mailto:finecobankspa.pec@actaliscertymail.it) or Complaints Handling Officer at Fineco Asset Management DAC: 6<sup>th</sup> Floor, Block A, Georges Quay Plaza, Dublin 2, D02 V002, Ireland, or by email to: [complaints@finecoassetmanagement.com](mailto:complaints@finecoassetmanagement.com).

## Other relevant information

Copies of the English prospectus of the ICAV, the latest annual and semi-annual reports, details of the remuneration policy of the Manager, the latest share prices as well as other practical information such as the key information documents (in English and in Italian) as well as the past performance information can be obtained free of charge upon request from the registered office of the Manager and online at: [www.finecoassetmanagement.com](http://www.finecoassetmanagement.com). There is insufficient data on this share - class to provide a useful indication of past performance to investors.

- Depository: BNP Paribas Securities Services, Dublin Branch.
- Taxation: The Sub-Fund is subject to the tax laws and regulations of Ireland. Depending on your country of residence, the tax legislation of Ireland may have an impact on your personal tax position.
- Responsibility for information: The Manager may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the ICAV's prospectus.
- Fund structure: The Sub-Fund is a sub-fund of FAM Series UCITS ICAV, which is an Irish Collective Asset-management Vehicle with a range of sub-funds. The assets and liabilities of each sub-fund are segregated by law from those of other sub-funds. The prospectus and the annual and semi-annual reports of the ICAV are prepared for the entire range.
- To place orders: Instructions on how to buy, convert or redeem shares are set out in the prospectus. Shareholders may have the right to convert shares of this Sub-Fund into the same class of shares of another sub-fund of the ICAV.
- Authorisation: The ICAV and the Manager are authorised and regulated by the Central Bank of Ireland.
- Registered office: Fineco Asset Management DAC of 6th Floor, George's Quay, Dublin 2, Ireland.

Past performance is not a reliable indicator of future performance. Markets could develop very differently in the future. It can help you to assess how the Sub-Fund has been managed in the past.